Memantina Sandoz (Memantine Hydrochloride)

Memantine is a non‑competitive antagonist of the NMDA receptor. By blocking excessive activation of this receptor, it reduces calcium influx and protects neurons from glutamate‑induced excitotoxicity, a key process involved in the neurodegeneration seen in Alzheimer’s disease.

The dosing regimen for Memantina Sandoz is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Physicians typically start with a low dose and titrate upward as needed, following clinical guidelines.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Memantine belongs to the NMDA receptor antagonist class, which differs from cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors increase acetylcholine levels, memantine reduces excitotoxic glutamate activity. Both classes may be used alone or together, depending on disease stage and physician assessment.

Memantina Sandoz should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse reactions, although rare, can include seizures, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergence of suicidal thoughts or behavior. Patients should be monitored closely for any new or worsening symptoms.

Memantina Sandoz is contraindicated in patients with known hypersensitivity to memantine or any of the tablet’s excipients. Caution is also advised for individuals taking other NMDA antagonists or those with uncontrolled severe renal impairment.